## Abstract To assess the frequency and prognostic impact of Ep‐CAM and Her‐2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow‐up of 10.8 years were enrolled in this retrospective study
Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors
✍ Scribed by Franco Rilke; Maria Ines Colnaghi; Natale Cascinelli; Salvatore Andreola; Maria Teresa Baldini; Rosaria Bufalino; Giuseppe Della Porta; Sylvie Ménard; Marco A. Pierotti; Alessandro Testori
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 531 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Archival surgical specimens from I ,2 I0 female breast cancer patients treated between 1968 and 1971 and with a 19year follow-up were reanalyzed with special reference to several parameters, such as size of the primary tumor, axillary nodal involvement, histologic grade, degree of inflammatory infiltrate (LPI) of the tumor and expression of the neu oncoprotein (p185) as detected by immunohistochemistry. In a multifactorial analysis the 4 former factors were found to be independent prognostic parameters. Over-expression of p I85 was found to be related to tumor size and grade and to LPI but not to pathologic nodal status. Over-expression of p185 showed a negative impact upon survival in node-positive but not in node-negative patients. However, in the subset of node-negative patients without LPI, p I85 over-expression showed the same correlation with a poor prognosis as in node-positive patients. In contrast, in node-negative and LPIpositive patients, p I85 over-expression correlated with a good prognosis. Also, the prognosis of patients with positive nodes, presence of LPI and no p I85 over-expression was similar to that of patients with negative nodes, absence of LPI and pi85 over-expression. 6To whom correspondence and reprint requests should be sent.
📜 SIMILAR VOLUMES
The total cellular p185 HER-2/neu protein (p185) content was measured by ELISA in 346 invasive primary breast cancers, and the results were compared with those of estrogen (ER) and progesterone (PR) receptors, pS2 and Cathepsin D (Cat D) content. At a cut-off level of 260 fmol/mg protein, 53 of the
## Abstract Assessment of __HER2/neu__ oncogene has been used as both a prognostic and predictive marker for breast cancer. However, the choice of the best method to assess the status of __HER2/neu__ oncogene in breast cancer tissue remains controversial. A variety of techniques are available to de
Total tumor cathepsin D (TCD) levels were determined prospectively by a radioimmunometric assay in tumor c y t o d of 858 primary breast cancer patients diagnosed between 1989-1991. In 581 of these patients, tumor HER-l/neu oncogene amplification was simultaneously determined. In a "traininset" of 3
## Abstract ## BACKGROUND Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer with poorly understood prognostic variables. The purpose of this study was to define the prognostic impact of HER‐2 status on survival outcomes of patients with IBC. ## METHODS In all, 179 pati